Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia.

@article{Arnsten2017NovelDT,
  title={Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia.},
  author={Amy F. T. Arnsten and Ragy R. Girgis and David L F Gray and Richard B. Mailman},
  journal={Biological psychiatry},
  year={2017},
  volume={81 1},
  pages={67-77}
}
Schizophrenia is characterized by profound cognitive deficits that are not alleviated by currently available medications. Many of these cognitive deficits involve dysfunction of the newly evolved, dorsolateral prefrontal cortex (dlPFC). The brains of patients with schizophrenia show evidence of dlPFC pyramidal cell dendritic atrophy, likely reductions in cortical dopamine, and possible changes in dopamine D1 receptors (D1R). It has been appreciated for decades that optimal levels of dopamine… CONTINUE READING